In comparison, the co-overexpression of MYC and BCL2 and/or BCL6 proteins, so-called dual expressors (DE-DLBCL) or triple expressors(TE-DLBCL) detected by Immunohistochemistry(IHC) is much more common, occurring in 20–30% DLBCL patients. Here, MYC is linked to diffuse large B-cell lymphoma.